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Desquamative Gingivitis: Early Presenting Symptom of Mucocutaneous Disease 
Abstract 
Desquamation of the gingiva is a sign that may be encountered in clinical practice. Various diseases can 
affect the gingival tissues. Mild desquamation that is localized may be associated with mechanical 
irritation or induced by trauma. Moderate to severe generalized desquamation associated with ulceration 
and erythema may be indicative of a more serious systemic condition. Although often overlooked, 
mucocutaneous diseases frequently present with gingival desquamation as an early presenting symptom. 
The most common mucocutaneous diseases that affect the oral cavity are lichen planus, pemphigus, and 
mucous membrane pemphigoid. This article reviews the etiology, signs and symptoms, and therapies for 
these disorders. Increased knowledge of mucocutaneous diseases can help the clinician recognize these 
disorders and enable the patient to receive appropriate therapy. 
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Desquamative gingivitis: Early presenting symptom of 
mucocutaneous disease 
Eric T. Stoopler, DMD'fThomas P. Sollecito, DMD2/Scott S. DeRossi, DMD' 
Desquamation of the gingiva is a sign that may be encountered in clinical practice. Various diseases can 
affect the gingival tissues. Mild desquamation that is localized may be associated with mechanical irritation 
or induced by trauma. Moderate to severe generalized desquamation associated with ulceration and ery-
thema may be indicative of a more serious systemic condition. Although chen overlooked, mucocutaneous 
diseases frequently present with gingival desquamation as an early presenting symptom. The most com-
mon mucocutaneous diseases that affect the oral cavity are lichen planus, pemphigus, and mucous mem-
brane pemphigoid. This article reviews the etiology, signs and symptoms, and therapies for these disor-
ders. Increased knowledge of mucocutaneous diseases can help the clinician recognize these disorders 
and enable the patient to receive appropriate therapy. (Quintessence lnt 2003;34:582-586) 
Key words: desquamative gingivitis, erosive lichen planus, mucous membrane pemphigoid, pemphigus 
vulgaris, reticular lichen planus 
G ingival tissue can be differentiated based on its anatomic position. The free gingiva comprises the 
gingival tissue at the vestibular and lingual/palatal as-
pects of the teeth and in health, is coral pink and has 
a dull surface and firm consistency.' The attached gin-
giva extends apically from the free gingiva to the 
mucogingival junction, where it becomes contiguous 
with the darker red alveolar mucosa. The alveolar mu-
cosa is loosely bound to the underlying bone and is 
relatively mobile. The attached gingiva is firm ly adher-
ent to the underlying alveolar bone and in health, is 
coral pink and often shows a fine, surface stippling, 
giving it the appearance of an orange peel. ' 
Desquamation or peeling of the epithelial tissue 
usually occurs mainly on the free and attached gin-
giva. Mild cases that are localized and display minimal 
loss of tissue with mild erythema and no ulceration 
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may be attributed to mechanical abrasion or irritation. 
Aggressive toothbrushing or parafunctional habits may 
cause these localized forms of gingival desquamation. 
Various oral hygiene products may also cause a mild 
superficial peeling of the gingiva. Toothpaste hyper-
sensitivity, especially to tartar-control products, has 
been reported as an etiology of desquamative gingivi-
tis.2 The patient should be educated on proper tooth-
brushing techniques and encouraged to discont inue 
parafunctional habits if these are the suspected etiolo-
gies. More severe desquamation may be generalized 
and accompanied by intense erythema and ulcerations 
on the free and attached gingiva, as well as the alveo-
lar mucosa. When local factors cannot be attributed to 
the etiology of the desquamation, systemic conditions 
must be considered. Three common mucocutaneous 
diseases that can present with initial symptoms of 
desquamative gingivitis (peeling of the gingival tissue 
usually accompanied by erythema, ulceration, and 
pain) are lichen planus, pemphigus, and mucous mem-
brane pemphigoid. These conditions are immune me-
diated and are managed via topical and/or systemic 
medications. Knowledge of the etiology, s igns and 
symptoms, and therapies for these diseases will enable 
the clinician to more effectively recognize and diag-
nose these conditions. 
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LICHEN PLANUS 
Lichen planus (LP) is a relatively common dermato-
logic disorder that occurs on the skin and oral mucous 
membranes. There are several forms of this disease, in-
cluding reticular, papular, atrophic, bullous, and ero-
sive patterns. This discussion will focus on the reticu-
lar and erosive forms of LP. 
The reticular form of LP is the most common and 
most readily recogn ized form of the disease. It consists 
of slightly elevated. fine, whitish lines (Wickham 's 
striae) that produce a lacelike lesion.' Reticular LP is 
most commonly seen bilaterally on the cheeks and is 
usually asymptomatic requiring no treatment. 
Erosive LP presents as chronic multiple oral mu-
cosal ulcers. A significant number of cases of erosive 
LP presents with an initial sign of erythema and/ or 
desquamative gingivitis' Figure 1 demonstrates gener-
alized desquamative gingivitis in a patient diagnosed 
with erosive LP. In some cases, the lesions start as 
vesicles or bullae (bullous LP), and in others, the dis-
ease is characterized solely by erythema or ulcers (ero-
sive LP). The etiology of LP is idiopathic, which distin-
guishes itself from lichenoid react ions. Li chenoid 
reactions have a similar clinical presentation to LP but 
are differentiated on the basis of the association of the 
reactions \vith administration of a drug, systemic dis-
ease, or contact allergy, and they may slowly resolve 
when the allergen is discontinued or the disease is 
t reated. Drugs that have been reported to induce 
lichenoid reactions are penicillamine, ACE inhibitors, 
and nonsteroidal anti-inflammatory drugs (NSA!Ds), 
al though, less commonly, numerous other drugs have 
been implicated.' Contact allergens such as cinnamon 
and peppermint, as well as mercury and gold in select 
d ental ma te rials have been reported to cause a 
lichenoid reaction due to contact allergy.' Hepatitis C 
is a systemic condition that has been implicated with 
induction of LP-Iike lesions• 
The diagnosis of LP and lichenoid reactions is 
made by biopsy. Three characteristic features of LP are 
seen histologically: a dense subepithelial band of lym-
phocytes; liquefactive degeneration of the basal cell 
layer; and areas of hyperorthokeratosis and hyper-
parakeratosis with a saw tooth appearance to the rete 
pegs.1• Lichenoid reactions cannot always be distin-
guished from LP but may show deep, as well as super-
ficial lymphocytic infiltrates, rather than the classic 
bandlike infiltrate of LP, as well as eosinophils, neu-
trophils, and plasma cells. Direct immunofluorescence 
can be performed mainly to rule out other mucocuta-
neous diseases, such as pemphigus or mucous mem-
brane pemphigoid. Subepithelial deposits of fibrinogen 
are the most consistent feature of LP when analyzed 
via immunofluorescence. 
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Fig 1 Generalized desquamation and erythema in the maxillary 
and mandibular ging1vae of a pat1ent d1agnosed with erosive 
lichen planus 
Treatment of LP/ lichenoid reactions can be wide 
ranging. If the patient has been using navoring agents, 
they should be advised to discontinue the use of such 
products. If the patient has started a new medication 
that correlates to the onset of LP, they should discuss 
changing classes of medication with their physician. 
The erosive type of LP should be managed more ag-
gressively with the use of high potency (fluocinonide) 
and ultra high potency (clobetasol) topical steroid 
gels. These agents may be placed in an occlusive den-
tal splint that covers the affected area of the gingiva to 
increase healing time and decrease pain. Topical 
steroid rinses and topical steroids applied to gauze 
pads are other methods of administering medication. 
Intralesional steroid injections may be necessary to 
treat lesions that are recalcitrant to conventional ther-
apy; however, this may be difficult for gingival lesions. 
A short course of systemic steroids may be considered 
for extremely indolent lesions• Recently, several re-
ports have been published regarding the use of topical 
tacrolimus in treating oral lichen planus. Tacrolimus is 
an immunosuppressive agent used in the prevention of 
solid organ transplant reject ion, and several reports 
have been published demonstrating the effectiveness 
of the topical formulation in managing oral LP, espe-
cially lesions recalcitrant to conventional therapyiD- 13 
There is evidence that suggests that patients with ero-
sive LP are of a higher risk for developing squamous 
cell carcinoma. Therefore, it is important to evaluate 
these patients on a standard recall basis. This recall 
should be based on the patient's response to treat-
ment. Areas unresponsive to treatment should be re-
biopsied to rule out dysplasia. Often, the recall will be 
more frequent than that usually performed for perio-
dontal disease, usually every 1 to 3 months. 
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Fig 2 Generalized 1ntense erythema and areas of desquamation 
m the max1llary and mandibular gingivae of a pat1ent diagnosed 
w1th pemphigus vulgaris 
An important aspect of LP that must be appreciated 
by the clinician is the chronic nature of this disease. 
Lichen planus, when properly managed, can undergo 
periods of quiescence where the patient does not ex-
perience any symptoms. When the condition becomes 
exacerbated, it can cause desquamation of the gingiva, 
which may lead to severe and painful gingivitis. This 
may cause the patient to neglect daily oral hygiene due 
to the painful nature of these symptoms and may, in 
turn, lead to an increase in gingival infl ammation and 
periodontal disease. More frequen t professional pro-
phylaxis may be indicated. Due to the chronic nature 
of LP, periodontal therapy becomes more integral in 
the maintenance of oral health in these patients, as 
poor periodontal health makes the management of 
erosive LP extremely difficult. 
PEMPHIGUS 
Pemphigus is an autoimmune disease characterized by 
blisters, peeling, and erosions of the skin and mucous 
membranes. The highest incidence of the disease occurs 
in the fifth and sixth decades of life." This discussion 
will be limited to the most common fonn of the disease, 
pemphigus vulgaris (PV), which accounts for over 80% 
of cases. The other fonns of pemphigus are pemphigus 
vegetans, pemphigus foliaceus, pemphigus erythemato-
sus, paraneoplastic pemphigus (a condition where pa-
tients with neoplasms, such as lymphoma, present wtth 
pemphigus), and drug-related pemphigus15 . . 
Lesions associated with PV are mtraeptthehal, and 
blister formation is initiated by the binding of IgG au-
toantibodies to desmoglein 3, a transmembrane glyco-
protein adhesion molecule present on desmosomes. 
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Once desmoglein 3 is bound by the autoantibody, 
there is loss of cell-to-cell adhesion and blister forma-
tion begins. As blister formation p~ogresses, it results 
in a suprabasilar bulla, which can involve loss of large 
areas of skin and mucosal> 
Initial signs of PV may include generalized desqua-
mative gingivitis, as seen in Fig 2. The classical oral le-
sion of pemphigus is a thin-walled bulla with associ-
ated erythema. The lesions are commonly seen on the 
gingival and buccal mucosa, and the edges of the le-
sion can continue to extend peripherally until they in-
volve large areas of the oral mucosa. It is common for 
the oral lesions to present up to 4 months before the 
skin lesions appear. If treatment is instituted during 
this time, the disease will be easier to control, and the 
chance for early remission is enhanced15 
Biopsy is the standard for diagnosing PV. Ideally, 
the biopsy specimen should be taken from an intact 
vesicle less than 24 hours old. Since these types of le-
sions are rarely present in the mouth , the biopsy 
should be taken from the advancing edge of the lesion 
where the characteristic suprabasilar splitting of the 
epithelium may be observed. A second biopsy speci-
men should be taken from clinically normal-appearing 
intact perilesional mucosa and sent fo r direct im-
munofluorescene studies (DIP). Direct immunofluo-
rescene is performed by placing fluorescene-labeled 
antihuman immunoglobulins over the patient's tissue 
specimen in order to detect antibodies bound to the 
surface of keratinocytes. If the patient is positive for 
PV, the immunofluorescence pattern will reveal a lace-
like pattern around the epithelial cells of the tissue 
specimen. 
The mainstay of treatment is high doses of systemic 
corticosteroids. P rednisone is initially used to bring 
the disease under control and once this is achieved, 
the dose of prednisone is decreased to the lowest pos-
sible maintenance level. A critical aspect of patient 
management is early diagnosis; this allows the clini-
cian to use lower doses of medication for shorter peri-
ods of time to control the disease. Azathioprine and 
cyclophosphamide are immunosuppressive drugs used 
as adjuvant therapies in conjunction with prednisone 
to reduce side effects of the steroid 16 by allowing the 
clinician to administer lower doses of systemic steroid. 
Studies have shown that adjuvant therapy decreases 
mortality when used with systemic corticosteroids. ~ 18 
Mycophenolate mofetil, a newer immunosuppressive 
drug, has been effective in managing patients resistant 
to other adjuvants 1 9 Current studies have demon-
strated the effectiveness of mycophenolate in combi-
nation with prednisone to successfully manage PV 
while managing adverse side effects of medication.2o 
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MUCOUS MEMBRANE PEMPHIGOID 
Mucous membrane pemphigoid (MMP), also com-
monly referred to as cicatricial pemphigoid, is a 
chronic, autoimmune disease that results in mucosal 
ulceration and subsequent scarring. It primarily affects 
the mucous membranes of patients over the age of 50 
and is considered a subepithelial disease' ' Auto-
antibodies, usually of the lgG class, cause subepithelial 
blistering by cleaving fibrils in the basement mem-
brane zone, as well as activating complement and re-
cruiting neutrophils.21 Subsets of MMP have been 
identified using sophisticated immunology testing and 
salt-split skin. These subsets are based on the location 
and molecular weight of the antigens involved in 
M M P, and the majority of cases have antigens on the 
epidermal side of salt-split skin.22 Today, MMP is con-
sidered a family of closely related autoimmune disor-
ders in which the various autoantigens are found in 
the BMZ and are involved in the attachment of basal 
epithelial cells to the underlying connective tissue. 
Oral manifestations of M M P include desquamative 
gingivitis and erosion or ulcerations of buccal and 
labial mucosa, palate, and tongue. Figure 3 demon-
strates intense erythema and an area of hemorrhage in 
the gingiva of a patient with MMP. Extraoral manifes-
tations include ulceration and scarring of the conjunc-
tiva, corneal damage, and mucosal lesions of the geni-
tals, esophagus, larynx, and trachea."' Skin involvement 
is seen in a low percentage of patients with MMP'' 
Any patient suspected of having MMP must have 
two biopsy specimens taken for both routine histology 
and direct immunofluorescence study. Routine 
histopathology will demonstrate sub-basilar cleavage 
and immunofluorescence will show positive fluores-
cence for immunoglobulin and complement in the 
basement membrane zone in 50% to 80% of patients." 
Clinical correlation with routine and immunofluores-
cence studies shou ld be interpreted together to arrive 
at a diagnosis of MMP. 
Management of MMP depends on the severity of 
symptoms. Patients with mild oral disease may be 
managed by topi cal and intralesional steroids. 
Desquamative gingivitis is often managed with topical 
steroids in a soft occlusive splint that covers the gin-
giva. An adverse sequela of chronic topical steroid use 
is candida! infection, and the clinician must closely 
monitor the patient for development of infection. 
If topical therapies prove ineffective, systemic medi-
cations may be used for treatment. Like PV, systemic 
steroids are often effective. Dapsone is a synthetic sul-
fone with anti-inflammatory properties that is found 
to be most effective in diseases associated with signifi-
cant neutrophil infiltration. It has been in clinical use 
for many years to treat leprosy and malaria. Studies 
Quintessence International 
Fig 3 Area of hemorrhage and 1ntense erythema m the maxtllary 
ging1va of a pat1ent d1agnosed w1th mucous membrane pem-
phiQOid. 
have demonstrated its effectiveness in treating mucous 
membrane pemphigoid.2124 The major adverse effect of 
dapsone is hemolysis, and pr ior to initiating therapy, 
patients should be screened for glucose-6-phosphate 
dehydrogenase (G6PD) deficiency. This is a key en-
zyme that prevents oxidation of hemoglobin to methe-
moglobin, and individuals who are G6PD deficient 
may develop extensive hemolysis.25 Minocycline, a 
member of the tetracycline fami ly of antibiotics, also 
has been shown to be effective in treating MMP.2 • 
Reported adverse effects include nausea, vomiting, 
dizziness, photosensitivity, and hyperpigmentation." 
Combination therapies consisting of nicotinamide and 
tetracycline also have been reponed as effective ther-
apy for MMP.27 It is very important for the clinician to 
thoroughly examine all skin surfaces and the patient's 
eyes to determine the extent of the M M P. If extraoral 
manifestations are observed, it is imperative that the 
patient be referred to the appropriate specialist for fur-
ther evaluation. It is important to remember that ap-
proximately 10% of patients with MMP will develop 
eye lesions which often result in scarring and can lead 
to blindness. 
CONCLUSION 
Gingival desquamation can be indicative of local 
trauma/ irritation or systemic disease. Lichen planus, 
pemphigus, and mucous membrane pemphigoid are 
three mucocutaneous diseases that can present with 
gingival desquamation as their initial symptom. With a 
comprehensive history and physical exam, as well as 
the use of gingival biopsy, diagnosis of these disorders 
will not be delayed. 
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